| Literature DB >> 35268210 |
Daniel Bravo-Barriga1, Francisco J Serrano-Aguilera1, Rafael Barrasa-Rita2, Miguel Ángel Habela1, Rafael Barrera Chacón2, Luis Javier Ezquerra2, María Martín-Cuervo2.
Abstract
Endurance is an increasingly popular equestrian sport. However, in southern Europe, there is a high prevalence of horses that are asymptomatic carriers of equine piroplasmosis (EP), a tick-borne disease that could affect their performance. This study aimed to evaluate the impact and influence of EP on the performance of endurance horses. Blood samples were collected from 40 horses in Extremadura, Spain, before and after a race, in different national elite horse endurance competitions. Hematological and biochemical parameters and EP seroprevalence were analysed by competitive enzyme-linked immunosorbent assay. The global seroprevalence of EP was 70%, with 27 horses testing positive for Theileria equi (67.5%) and three (7.5%) for Babesia caballi, with two of these horses (5%) positive for both. Approximately 82.5% of the horses (33 of 40) completed the competition, with no influence on performance or position achieved in those with subclinical parasitosis. There were also no significant differences in hematological or biochemical values between seropositive and seronegative horses. The data suggest that horses without clinical signs of EP can participate without performance impairment in competitions of up to 80 km. Although it is recommended that longer distance competitions should be further evaluated, this is the first step for decision-making by organizers and participants in this sport.Entities:
Keywords: ELISA; Theileria equi; endurance; equine piroplasmosis; hematology; performance
Year: 2022 PMID: 35268210 PMCID: PMC8909285 DOI: 10.3390/ani12050637
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 2.752
Figure 1Box and whisker plots of the race position (y-axis) of positive and negative horses to T. equi (orange and green groups, respectively) by competitive enzyme-linked immunosorbent assay (cELISA) in the three-race modalities (x-axis). The horizontal line within each box represents the median race position of each group. Top and bottom box boundaries limit the interquartile range (IQR) between the first and third quartiles (25−75% of positions), and therefore boxes represent midspread (50% of less extreme positions). Whiskers show confidence limits based in the range of cases within 1.5 times the IQR. The dots show individual arrival positions according (horizontal jitter within groups is only to avoid dot overlapping). The colour of dots represents the percentage of inhibition PI in cELISA according to the colour scale wheaten red (high PI) and blue (low PI).
Figure 2Hierarchical clustering via multiscale bootstrap resampling (n = 10,000) of arrival position in endurance horses with hematological and biochemical variables before and after the race, and with BPM controls (BPM1 to BPM4) during the competition. Repeated measures are indicated by the number of suffixes. Red numbers are the percentage of the signification of each cluster based on approximately unbiased p-values (au). Red rectangles show major significant clusters. AST: aspartate aminotransferase; CK: creatinine kinase; Fe: Iron; Ht: hematocrit value; LDH: lactate dehydrogenase; RBC: red blood cells; TP: total proteins; WBC: white blood cells.
Figure 3Box and whiskers plot of beats per minute (BPM) in veterinary controls (vet-control) before the race (1) and in vet-gates (2–4) in seronegative horses (green boxes) and ELISA-positive horses to EP (orange boxes).
Summary of mean ± standard deviation (SD) of hematologic and biochemistry parameters values depending on the presence of equine piroplasmosis (EP) and performance of the exercise.
| Global Group | Seropositive EP | Seronegative EP | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | Reference Values | n1 | n2 | Before | After | Before | After | Before | After | ||
| RBC (1012/L) | 6.40−10.40 | 40 | 39 | 8.2 ± 1.1 | 9.0 ± 1.7 | 0.0046 | 8.2 ± 1.2 | 9.0 ± 1.9 | 8.3 ± 1.2 | 9.0 ± 1.9 | 0.41 |
| Ht (%) | 30−47 | 40 | 40 | 37.7 ± 5.3 | 41.2 ± 5.7 | 4.8 × 10−4 | 37.1 ± 5.2 | 40.6 ± 5.9 | 38.9 ± 5.2 | 42.6 ± 5.9 | 0.12 |
| WBC (109/L) | 4.90−11.10 | 40 | 39 | 8.5 ± 1.8 | 10.8 ± 2.6 | 9.2 × 10−8 | 8.4 ± 1.8 | 10.8 ± 2.6 | 8.7 ± 1.8 | 11.0 ± 2.6 | 0.34 |
| TP (g/L) | 56−79 | 40 | 40 | 71 ± 6 | 75 ± 7 | 37 × 10−4 | 71 ± 6 | 74 ± 8 | 70 ± 6 | 77 ± 8 | 0.08 |
| Iron (µmol/L) | 18.8−49.6 | 38 | 37 | 28.5 ± 4.5 | 29.4 ± 10.2 | 3.7 × 10−4 | 28.1 ± 4.1 | 30.1 ± 11.8 | 29.5 ± 4.1 | 27.6 ± 11.8 | 0.68 |
| CK (U/L) | 10−350 | 38 | 38 | 88 ± 57 | 371 ± 281 | 1.8 × 10−10 | 90 ± 59 | 350 ± 256 | 85 ± 59 | 417 ± 256 | 0.33 |
| LDH (U/L) | 250−2070 | 37 | 39 | 592 ± 354 | 1039 ± 601 | 3.6 × 10−5 | 575 ± 388 | 1027 ± 704 | 600 ± 388 | 1066 ± 704 | 0.25 |
| AST (U/L) | 100−600 | 38 | 38 | 176 ± 59 | 214 ± 76 | 0.0018 | 167 ± 64 | 224 ± 65 | 197 ± 64 | 193 ± 65 | 0.36 |
p-value comparing the average of both measures in each animal. n1 = animals evaluated before exercise; n2 = animals evaluated after exercise; EP: equine piroplasmosis; RBC: red blood cells; Ht: hematocrit value; WBC: white blood cells; TP: total proteins; CK: creatinine kinase; LDH: lactate dehydrogenase; AST: aspartate aminotransferase.
Figure 4Box and whiskers plot of several hematological and biochemical parameters (y-axis) before and after the endurance challenge (x-axis) in 40 horses according to the diagnosis of theileriosis by competitive enzyme-linked immunosorbent assay (cELISA) (orange and green groups, respectively). The horizontal line within each box represents the median of each parameter. Top and bottom box boundaries limit the interquartile range (IQR) between the first and third quartiles. Whiskers show the range of cases within 1.5 times the IQR. The colour of dots represents the percentage of inhibition PI in cELISA according to the colour scale wheaten red (high PI) and blue (low PI). (A) RBC: red blood cells; (B) WBC: white blood cells; (C) Ht: hematocrit value; (D) TP: total pro-teins; (E) CK: creatinine kinase; (F) LDH: lactate de-hydrogenase; (G) AST: aspartate ami-notransferase.